Metraipolis › archive › dc_5702ffa3df30

Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries — Europe PMC PMID:42769105

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42769105
DOI
10.3389/fphar.2026.1904028
License (as archived)
solo-consultazione
Archived
2026-10-15T23:26:01.340Z
SHA-256 of the archived text
08baf3e0a78b0b13c6a3eac58c428581a8e064caf25dd93261d7cc766042363e
Stable URL of this page
https://metraipolis.com/documento/dc_5702ffa3df30

How to cite

Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries — Europe PMC PMID:42769105 — Europe PMC (en), https://europepmc.org/article/MED/42769105 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5702ffa3df30 (Metraipolis archive dc_5702ffa3df30, sha256 08baf3e0a78b0b13c6a3eac58c428581a8e064caf25dd93261d7cc766042363e)
BibTeX
@misc{dc5702ffa3df30,
  title = {Tyrosine kinase inhibitors for chronic myeloid leukemia: a landscape analysis of global clinical trials based on public registries — Europe PMC PMID:42769105},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42769105},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5702ffa3df30; sha256 08baf3e0a78b0b13c6a3eac58c428581a8e064caf25dd93261d7cc766042363e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42769105. Agents can read the archived copy with the MCP tool read_document.